Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Literature DB >> 2550233

Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

V Preac-Mursic¹, B Wilske, G Schierz, E Süss, B Gross.

Abstract

The in vitro and in vivo activity of the new macrolides azithromycin, clarithromycin and roxythromycin was compared with that of erythromycin against Borrelia burgdorferi. In in vitro tests using ten clinical isolates all macrolides were highly active against Borrelia burgdorferi (MIC90 0.015-0.06 micrograms/ml). Azithromycin was more potent than the other macrolides in experimental animal infection, eradicating the organism in all animals tested at a dosage of 8 mg/kg.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2550233 DOI： 10.1007/BF01968150

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

8 in total

1. Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.

Authors: G A Dette; H Knothe; G Koulen
Journal: Drugs Exp Clin Res Date: 1987

2. Serological diagnosis of erythema migrans disease and related disorders.

Authors: B Wilske; G Schierz; V Preac-Mursic; K Weber; H W Pfister; K Einhäupl
Journal: Infection Date: 1984 Sep-Oct Impact factor: 3.553

3. Treatment of Lyme disease.

Authors: K Weber
Journal: Ann Intern Med Date: 1981-01 Impact factor: 25.391

4. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors: R C Johnson; C Kodner; M Russell
Journal: Antimicrob Agents Chemother Date: 1987-02 Impact factor: 5.191

5. In vitro and in vivo susceptibility of Borrelia burgdorferi.

Authors: V P Mursic; B Wilske; G Schierz; M Holmburger; E Süss
Journal: Eur J Clin Microbiol Date: 1987-08 Impact factor: 3.267

6. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Authors: A C Steere; A R Pachner; S E Malawista
Journal: Ann Intern Med Date: 1983-12 Impact factor: 25.391

7. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors: D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal: Antimicrob Agents Chemother Date: 1988-11 Impact factor: 5.191

8. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

Authors: V Preac-Mursic; B Wilske; G Schierz
Journal: Zentralbl Bakteriol Mikrobiol Hyg A Date: 1986-12

8 in total

25 in total

1. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors: R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal: Antimicrob Agents Chemother Date: 1990-11 Impact factor: 5.191

Review 2. Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors: Gary P Wormser; Ira Schwartz
Journal: Clin Microbiol Rev Date: 2009-07 Impact factor: 26.132

3. In vitro activity of trimethoprim against Borrelia burgdorferi.

Authors: E C Reisinger; I Wendelin; R Gasser
Journal: Eur J Clin Microbiol Infect Dis Date: 1997-06 Impact factor: 3.267

Review 4. Spectrum of activity of azithromycin.

Authors: J D Williams
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-10 Impact factor: 3.267

Review 5. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors: Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal: Expert Rev Anti Infect Ther Date: 2014-07-30 Impact factor: 5.091